A new biotech venture aiming to revolutionize cancer treatment by decoding tumor heterogeneity has raised $1.1M in seed funding. Cellyrix Therapeutics is pioneering a novel approach that combines single-cell sequencing and artificial intelligence to unlock insights into the complex variations within tumors.
This capital will support Cellyrix's work to develop innovative therapies, directly addressing tumor heterogeneity – a fundamental aspect of cancer that often leads to therapy resistance, metastasis, and relapse. By understanding these variations, the company seeks to introduce a new paradigm for treatment.
